Loading...
XLONOXB
Market cap564mUSD
Dec 24, Last price  
425.00GBP
1D
0.00%
1Q
14.86%
Jan 2017
108.85%
Name

Oxford Biomedica PLC

Chart & Performance

D1W1MN
XLON:OXB chart
P/E
—
P/S
502.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.88%
Rev. gr., 5y
6.04%
Revenues
90m
-36.04%
502,000824,000760,0007,219,00018,394,00019,120,00011,153,0007,718,0007,756,0005,375,00013,618,00015,909,00027,776,00037,590,00066,778,00064,060,00087,728,000142,797,000139,989,00089,539,000
Net income
-157m
L+248.75%
-10,464,000-9,085,000-17,626,000-15,289,000-10,041,000-3,515,000-10,290,000-12,631,000-8,730,000-11,096,000-8,661,000-13,019,000-16,641,000-9,017,0007,541,000-16,066,000-6,245,00019,011,000-45,159,000-157,490,000
CFO
-29m
L+126.06%
-10,366,000-8,342,000-17,128,0004,730,000-18,133,0002,314,000-12,828,000-12,983,000-10,037,000-11,019,000-6,032,000-13,118,000-5,106,0002,979,00012,868,000-3,508,0003,116,00025,455,000-12,615,000-28,517,000
Earnings
Apr 28, 2025

Profile

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
URL
https://www.oxb.com/
IPO date
Nov 15, 1996
Employees
894
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
89,539
-36.04%
139,989
-1.97%
142,797
62.77%
Cost of revenue
134,578
159,968
115,498
Unusual Expense (Income)
NOPBT
(45,039)
(19,979)
27,299
NOPBT Margin
19.12%
Operating Taxes
(4,365)
(817)
869
Tax Rate
3.18%
NOPAT
(40,674)
(19,162)
26,430
Net income
(157,490)
248.75%
(45,159)
-337.54%
19,011
-404.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
651
80,154
51,600
BB yield
-0.31%
-19.10%
-4.90%
Debt
Debt current
3,654
3,295
853
Long-term debt
180,728
185,487
17,829
Deferred revenue
5,331
1,145
1,852
Other long-term liabilities
17,058
46,606
6,244
Net debt
80,666
42,464
(93,941)
Cash flow
Cash from operating activities
(28,517)
(12,615)
25,455
CAPEX
(9,832)
(16,296)
(9,461)
Cash from investing activities
2,806
(56,462)
(9,461)
Cash from financing activities
(12,703)
98,622
46,207
FCF
35,242
(78,670)
19,618
Balance
Cash
103,716
141,308
109,018
Long term investments
5,010
3,605
Excess cash
99,239
139,319
105,483
Stockholders' equity
(302,499)
(118,874)
(120,427)
Invested Capital
514,180
514,751
323,303
ROIC
8.77%
ROCE
13.46%
EV
Common stock shares outstanding
96,555
94,830
85,619
Price
2.20
-50.28%
4.43
-64.02%
12.30
19.42%
Market cap
212,422
-49.38%
419,622
-60.15%
1,053,110
27.89%
EV
296,916
520,803
959,169
EBITDA
(16,329)
6,380
39,755
EV/EBITDA
81.63
24.13
Interest
11,199
16,729
888
Interest/NOPBT
3.25%